Level of HER2-neu Gene Amplification an Response to Trastuzumab
NCT ID: NCT00874146
Last Updated: 2010-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2009-03-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
NCT00740532
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
NCT00726180
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
NCT02560311
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NCT07047755
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
NCT01548677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
HER2-positive advanced breast cancer
Fluorescent in-situ hybridization (FISH)
Dual color FISH test to assess ratio of HER2/neu amplification
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluorescent in-situ hybridization (FISH)
Dual color FISH test to assess ratio of HER2/neu amplification
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Clinico Humanitas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Istituto Clinico Humanitas
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Armando Santoro, MD
Role: PRINCIPAL_INVESTIGATOR
Istituto Clinico Humanitas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Clinco Humanitas
Rozzano, Milan, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONC/OSS-03-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.